Cellectar Biosciences Company Profile (NASDAQ:CLRB)

Analyst Ratings

Consensus Ratings for Cellectar Biosciences (NASDAQ:CLRB) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Cellectar Biosciences (NASDAQ:CLRB)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Cellectar Biosciences (NASDAQ:CLRB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
11/12/2015Q315($0.25)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015Q215($0.30)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/21/2015Q115($0.30)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/26/2014($0.04)($0.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cellectar Biosciences (NASDAQ:CLRB)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.40)($0.40)($0.40)
Q3 20161($0.20)($0.20)($0.20)
Q4 20161($0.20)($0.20)($0.20)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cellectar Biosciences (NASDAQ:CLRB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cellectar Biosciences (NASDAQ:CLRB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/20/2016James V CarusoCEOBuy46,948$2.12$99,529.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/20/2016Paul L BernsDirectorBuy117,371$2.12$248,826.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/31/2015Awm Investment Company, Inc.Major ShareholderSell100,000$0.69$69,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2015Awm Investment Company, Inc.Major ShareholderSell82,847$0.69$57,164.43View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/28/2015Awm Investment Company, Inc.Major ShareholderSell367,966$0.73$268,615.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2015Awm Investment Company, Inc.Major ShareholderSell7,938$0.90$7,144.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/21/2015Awm Investment Company, Inc.Major ShareholderSell27,621$0.92$25,411.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2015Awm Investment Company, Inc.Major ShareholderSell71,225$0.87$61,965.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015Awm Investment Company, Inc.Major ShareholderSell44,965$0.82$36,871.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2015Awm Investment Company, Inc.Major ShareholderSell50,950$1.06$54,007.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2015Awm Investment Company, Inc.Major ShareholderSell173,802$1.24$215,514.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2015James V CarusoCEOBuy1,000$1.30$1,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2015Awm Investment Company, Inc.Major ShareholderSell96,806$1.17$113,263.02View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2015James V CarusoCEOBuy1,000$1.16$1,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2015James V. CarusoCEOBuy4,000$1.45$5,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2015Awm Investment Company, Inc.Major ShareholderSell8,866$2.00$17,732.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2015Awm Investment Company, Inc.Major ShareholderSell2,554$2.00$5,108.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/5/2015Awm Investment Company, Inc.Major ShareholderSell7,500$2.04$15,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Awm Investment Company, Inc.Major ShareholderSell27,940$2.05$57,277.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2015Awm Investment Company, Inc.Major ShareholderSell24,801$2.36$58,530.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2014John NeisDirectorBuy268,711$3.75$1,007,666.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2014Simon PedderCEOBuy13,300$3.75$49,875.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cellectar Biosciences (NASDAQ:CLRB)
DateHeadline
07/22/16 10:46 AMCellectar Biosciences, Inc. (NASDAQ:CLRB): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/21/16 08:48 PMStockNewsNow.com : Publishes New SNNLive Video Interview with Cellectar Biosciences, Inc. Discussing Corporate Updates and Clinical Development
07/21/16 07:30 AMStockNewsNow.com Publishes New SNNLive Video Interview with Cellectar Biosciences, Inc. Discussing Corporate Updates and Clinical Development - [PR Newswire] - LOS ANGELES, July 21, 2016 /PRNewswire/ -- StockNewsNow.com , The Official MicroCap News Source™, today published an SNNLive Video Interview with Jim Caruso, President & CEO of Cellectar Biosciences, Inc. ...
07/20/16 04:24 PMIncreased Stock Volatility Watch: Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Engelwood Daily
07/20/16 03:03 PMCELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, -
07/20/16 10:46 AMCellectar Biosciences Incorporated (NASDAQ:CLRB) Sellers Covered 3.93% of Their Shorts - Consumer Eagle
07/20/16 10:46 AMEquity Roundup: Stock Performance Focus on Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Press Telegraph
07/20/16 07:30 AMCellectar Biosciences Appoints Jarrod Longcor Senior Vice President of Corporate Development and Operations - [GlobeNewswire] - MADISON, Wis., July 20, 2016-- Cellectar Biosciences, Inc., an oncology-focused biotechnology company, today announces the appointment of Jarrod Longcor as senior vice president of corporate development ...
07/19/16 03:22 PMEarnings Focus and Crowd Sourced Sentiment Review for Cellectar Biosciences, Inc. (NASDAQ:CLRB) - TGP
07/19/16 03:22 PMHeightened Volatility Spotted on Shares of: Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Engelwood Daily
07/19/16 03:22 PMInvestor Watch: Volatility Recap on Shares of: Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Engelwood Daily
07/18/16 08:18 AMIntraday Movers - Royal Dutch Shell, (NYSE:RDS-B), Cellectar Biosciences, (NASDAQ:CLRB) - Hot Stocks Point
07/18/16 08:00 AMSeeThruEquity Initiates Coverage on Cellectar Biosciences, Inc. (NASDAQ: CLRB) with a Price Target of $7.44 - [Accesswire] - NEW YORK, NY / ACCESSWIRE / July 18, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated ...
07/15/16 07:21 PMShares Dipping Down in Today's Session: Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Telanagana Press
07/15/16 02:19 PMHC Stocks in Drift: Cellectar Biosciences Inc (NASDAQ:CLRB), Exelixis, Inc. (NASDAQ:EXEL) - share market updates (press release)
07/14/16 08:43 PMCellectar Biosciences, Inc. (NASDAQ:CLRB) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/13/16 11:00 PMCELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements a -
07/13/16 08:39 PMCellectar Biosciences Incorporated (NASDAQ:CLRB) Short Interest Decreased By 56.47% - Consumer Eagle
07/12/16 03:21 PMCellectar Biosciences, Inc. (NASDAQ:CLRB) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/07/16 03:17 PMHeightened Volatility Check on: Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Engelwood Daily
07/05/16 08:00 AMBest Stocks: Cellectar Biosciences, (NASDAQ:CLRB), LinkedIn Corporation (NYSE:LNKD), New York & Company ... - KC Register
07/01/16 11:07 AMUpdate on Stock Volatility for: Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Engelwood Daily
06/30/16 03:30 PMCELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/29/16 11:21 AMTESARO : Why Investors Love These Biotech's Stocks? - Cellectar Biosciences, Xenoport, Rexahn Pharma, and Tesaro
06/27/16 03:17 PMMorning Watch List: Cartesian, Inc. (NASDAQ:CRTN), Cellectar Biosciences, Inc. (NASDAQ:CLRB), Comerica ... - KC Register
06/25/16 07:07 AMMylan NV (NASDAQ:MYL) & Cellectar Biosciences (NASDAQ:CLRB) are Hot Healthcare Stocks - Wall Street 24
06/24/16 03:22 PMCellectar Biosciences (CLRB) Announces Significant Data from NCI-Sponsored CLR 125 Phase 1 in TNBC
06/24/16 07:01 AMCellectar Biosciences, Inc. (NASDAQ:CLRB) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 07:01 AMActive Stocks on Frontline- Teva Pharmaceutical (NYSE:TEVA), Cellectar Biosciences (CLRB), Hertz Global (NYSE:HTZ) - Seneca Globe
06/23/16 04:45 PMCellectar Biosciences (CLRB) Announces Significant Data from NCI-Sponsored CLR 125 Phase 1 in TNBC - StreetInsider.com
06/23/16 10:13 AMMid-Morning Market Update: Markets Open Higher; BlackBerry Profit Tops Views
06/23/16 07:49 AMCellectar Biosciences Announces Results of NCI-Sponsored Study of CLR 125 Showing Potential Effect Against Triple Negative Breast Cancer - [at noodls] - MADISON, Wis., June 23, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) ('the company'), an oncology-focused biotechnology company, today announces the results of the first phase of ...
06/17/16 03:07 PMCellectar Biosciences, Inc. (NASDAQ:CLRB) Earns Consensus Hold Rating - iStreetWire
06/17/16 03:07 PMMost Volatile Healthcare Movers- Exact Sciences (NASDAQ:EXAS), Cellectar Biosciences (NASDAQ:CLRB) - Seneca Globe
06/17/16 03:07 PMEarnings Overview: Neovasc Inc. (NASDAQ:NVCN), Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Beacon Chronicle
06/17/16 03:07 PMCellectar Biosciences Inc. (CLRB) Climbed On Study Results - RTT News
06/17/16 03:03 PMCELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
06/16/16 08:34 PMCellectar Biosciences Inc : Biotechs Setup To Bounce Once Again
06/16/16 03:14 PMCellectar Biosciences (CLRB) Announces Positive Prelim. Results for CLR 1602 in Tumor Targeting
06/16/16 03:14 PMCellectar Biosciences Inc. (CLRB) Climbed On Study Results
06/16/16 07:38 AMHC Trending Hot Stocks: Cellectar Biosciences Inc (NASDAQ:CLRB), EXACT Sciences Corporation (NASDAQ:EXAS) - share market updates (press release)
06/16/16 07:38 AMCellectar Biosciences Inc. (CLRB) Is Up Sharply On Study Results - RTT News
06/15/16 03:20 PMCellectar Biosciences jumps after positive tumor study results
06/15/16 03:20 PMCellectar Biosciences Inc. (CLRB) Is Up Sharply On Study Results
06/15/16 03:20 PMCellectar Biosciences (CLRB) Stock Spikes 25 Percent on Promising New Data
06/15/16 08:00 AMCLR 1602 Tumor Selectivity Shown to be Approximately 30 Times Greater than Paclitaxel Alone
06/15/16 07:31 AM8:31 am Cellectar Biosciences announces the results of a preliminary tumor-targeting study that shows its prototype paclitaxel chemotherapeutic conjugate, CLR 1602, may be up to 30 times more tumor selective in comparison to free paclitaxel -
06/15/16 07:30 AMCellectar Biosciences Announces Results of In Vivo Study Demonstrating PDC Platform Delivery of Paclitaxel to be Superior in Tumor Targeting to Free Paclitaxel - [GlobeNewswire] - MADISON, Wis., June 15, 2016-- Cellectar Biosciences, Inc., an oncology-focused biotechnology company, today announces the results of a preliminary tumor-targeting study that shows its prototype paclitaxel ...
06/10/16 11:33 AMPrice Target by Analysts: UnitedHealth Group Incorporated (NYSE:UNH), Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Beacon Chronicle
06/08/16 03:50 PMInvestors Checklist Stocks: Nevro Corp. (NYSE:NVRO) , Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Street Updates

Social

About Cellectar Biosciences

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a biopharmaceutical company. The Company is engaged in developing compounds for the treatment, diagnosis and imaging of cancer. Its product candidates include I-124-CLR1404, I-131-CLR1404 and CLR1502. Its product candidates are based on a cancer-targeting delivery platform of optimized phospholipid ether (PLE) analogs that interact with lipid rafts. I-131-CLR1404 is a small-molecule, broad-spectrum, cancer-targeting molecular radiotherapeutic that is a radiotherapeutic agent to use PLEs to target cancer cells. CLR1502 is a small-molecule, broad-spectrum, cancer-targeting, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CLRB
  • CUSIP:
Key Metrics:
  • Previous Close: $2.67
  • 50 Day Moving Average: $3.24
  • 200 Day Moving Average: $3.73
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $10.23M
  • Beta: 0.29
  • Current Year EPS Consensus Estimate: $-0.8 EPS
  • Next Year EPS Consensus Estimate: $-0.83 EPS
Additional Links:
Cellectar Biosciences (NASDAQ:CLRB) Chart for Wednesday, July, 27, 2016